Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cadonilimab - Akeso Biopharma

Drug Profile

Cadonilimab - Akeso Biopharma

Alternative Names: AK-104

Latest Information Update: 22 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Akeso Biopharma
  • Developer Akeso Biopharma; Chipscreen Biosciences; Sun Yat-Sen University; The Third Affiliated Hospital of Soochow University
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T-lymphocyte antigen 4 inhibitors; Programmed cell death-1 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cervical cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cervical cancer
  • Preregistration Gastric cancer; Oesophageal cancer
  • Phase III Liver cancer; Non-small cell lung cancer
  • Phase II Nasopharyngeal cancer; Rectal cancer; Renal cell carcinoma; Solid tumours
  • Phase I/II Malignant melanoma; Pancreatic cancer; Peripheral T-cell lymphoma; Small cell lung cancer

Most Recent Events

  • 22 Apr 2024 Akeso Biopharma plans a phase III trial for Liver cancer (Combination therapy, In adults, In the elderly) in China (IV) in July 2024 (NCT06371157)
  • 08 Apr 2024 Updated efficacy data from the phase III COMPASSION-15 trial in Gastric cancer released by Akeso Biopharma
  • 02 Apr 2024 Akeso plans a phase III trial for Adenocarcinoma (Combination therapy, Second-line therapy or greater, Metastatic disease, Inoperable/Unresectable, Late-stage disease) (IV) in May 2024 (NCT06341335)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top